Pacira Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on June 11, 2013, by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.). The filing reports on the results of the Company's 2013 Annual Meeting of Stockholders held on June 11, 2013, and the subsequent appointment of a new director by the Board of Directors on June 12, 2013.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Corporate Actions
- Director Appointment: The Board appointed Mark A. Kronenfeld, M.D., as a Class I director effective June 12, 2013, serving until the 2015 Annual Meeting. Dr. Kronenfeld brings significant experience in anesthesiology and healthcare investment management.
- Annual Meeting Results:
- Proposal 1 (Election of Directors): Stockholders elected Paul Hastings, John Longenecker, and Andreas Wicki as Class II Directors. All three nominees received overwhelming support with over 22.6 million votes "For" each.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2013, with approximately 27.5 million votes "For".
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation with approximately 17.5 million votes "For" and 5.2 million votes "Against".
- Proposal 4 (Compensation Vote Frequency): Stockholders voted to hold future advisory votes on executive compensation annually (One Year), with approximately 20.7 million votes in favor.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, or specific risk factors. The document is limited to reporting the procedural outcomes of the shareholder meeting and the new director's background.
Investor Verification Checklist
- Verify the specific committee assignments for the newly appointed director, Mark A. Kronenfeld, M.D., as these were not determined at the time of filing.
- Review the definitive proxy statement filed on April 25, 2013, to confirm the standard compensation package for non-employee directors.
- Confirm the final financial results for the fiscal year ending December 31, 2013, as this 8-K does not contain financial performance data.